Drugs / Human Derived anti-BCMA CAR-T Injection
Human Derived anti-BCMA CAR-T Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05302648 | Feb 2022 → Dec 2024 overdue | plasma cell myeloma | Hrain Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Derived anti-BCMA CAR-T Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05302648 ↗ |
| Modality | Cell therapy | “Autologous genetically modified anti-BCMA CAR transduced T cells” NCT05302648 ↗ |